Company intelligence / Profile preview

Areteia Therapeutics

Chapel Hill, North Carolina, United Statesareteiatx.com ↗

Ownership: Private
Development stage: Other

Overview

Areteia Therapeutics’ lead candidate, dexpramipexole, is an oral small molecule inhibitor of eosinophil maturation. In Phase II studies for moderate-to-severe eosinophilic asthma, it demonstrated significant dose-dependent reductions in blood absolute eosinophil count and was well tolerated with no serious adverse events or discontinuations. The drug is now being evaluated in three pivotal global Phase III trials (EXHALE program) for severe eosinophilic asthma and one trial for COPD. Topline results from these studies are expected in 2025.

Therapeutic areas: Pulmonology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

dexpramipexole

Discontinued

Partnerships

Population Health Partners’ development unit Validae Health supports late-stage clinical development.

Beyond the preview

Go deeper on Areteia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Areteia Therapeutics.